Literature DB >> 19954638

[A comparative study on early toxicity of conditioning regimen with or without antithymocyte globulin].

Dai-hong Liu1, Jing Liu, Kai-yan Liu, Lan-ping Xu, Huan Chen, Yu-hong Chen, Wei Han, Yu Wang, Xiao-hui Zhang, Xian-jun Huang.   

Abstract

OBJECTIVE: To evaluate the toxicity of conditioning regimens of modified Bu/Cy +/- antithymocyte (ATG) in early stage after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS: A hundred patients with hematological malignancies undergoing allo-HSCT were assessed. Forty-two patients (group A) were conditioned with modified Bu/Cy regimen, 58 (group B) with modified Bu/Cy+ATG regimen. The occurrence of toxicity during the early stage after transplantation was evaluated and compared, including non-infectious fever, diarrhea, hepatotoxicity, mucositis and hematological toxicity.
RESULTS: In group A and B, the incidence of non-infectious fever was 4.8% vs 81.0%, transaminase elevation 59.5% vs 65.5%, bilirubin elevation 16.7% vs 48.3%, diarrhea 59.5% vs 79.3% and mucositis 45.2% vs 37.9%, respectively, white blood cells reached zero occurred at a median of +3 d and -3 d, the rate of red cell and platelet transfusion-dependence, within 10 days before transplantation was 11.9% vs 32.8 and 16.7% vs 82.8%, respectively.
CONCLUSIONS: Significant higher incidence of non-infectious fever, diarrhea, hepatotoxicity, leukopenia, and transfusion dependence is found and considered to be related to the administration of ATG in the conditioning regimen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19954638

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  1 in total

1.  Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation.

Authors:  L Binkert; M Medinger; J P Halter; D Heim; S Gerull; A Holbro; C Lengerke; M Weisser; J R Passweg
Journal:  Bone Marrow Transplant       Date:  2015-06-29       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.